An open-label, dose-escalation, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of XKH002 in patients with advanced solid tumors
Latest Information Update: 25 Oct 2024
At a glance
- Drugs XKH 002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kanova Biopharmaceutical
Most Recent Events
- 19 Jan 2024 New trial record